Arrowhead Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Arrowhead Pharmaceuticals's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 23.4% annually. Revenues have been growing at an average rate of 17.9% per year.
Key information
-33.13%
Earnings growth rate
-29.48%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 17.91% |
| Return on equity | -30.66% |
| Net Margin | -25.90% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Oct 07
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Sep 03Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
Aug 21
Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles
Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry
May 14Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 03Arrowhead Pharmaceuticals Is Finally Arriving
Mar 21Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Feb 19Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns
Feb 10Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Revenue & Expenses Breakdown
How Arrowhead Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 573 | -148 | 140 | 541 |
| 31 Mar 25 | 545 | -144 | 134 | 530 |
| 31 Dec 24 | 3 | -640 | 128 | 501 |
| 30 Sep 24 | 4 | -599 | 125 | 480 |
| 30 Jun 24 | 20 | -539 | 121 | 446 |
| 31 Mar 24 | 35 | -471 | 121 | 389 |
| 31 Dec 23 | 182 | -297 | 113 | 368 |
| 30 Sep 23 | 241 | -205 | 109 | 337 |
| 30 Jun 23 | 256 | -181 | 117 | 320 |
| 31 Mar 23 | 273 | -150 | 125 | 298 |
| 31 Dec 22 | 278 | -155 | 135 | 301 |
| 30 Sep 22 | 243 | -176 | 132 | 289 |
| 30 Jun 22 | 250 | -154 | 141 | 269 |
| 31 Mar 22 | 263 | -112 | 123 | 258 |
| 31 Dec 21 | 144 | -183 | 104 | 228 |
| 30 Sep 21 | 138 | -141 | 85 | 202 |
| 30 Jun 21 | 108 | -126 | 64 | 178 |
| 31 Mar 21 | 89 | -110 | 56 | 151 |
| 31 Dec 20 | 80 | -103 | 55 | 137 |
| 30 Sep 20 | 88 | -85 | 54 | 127 |
| 30 Jun 20 | 124 | -24 | 52 | 105 |
| 31 Mar 20 | 139 | 10 | 46 | 91 |
| 31 Dec 19 | 164 | 53 | 35 | 84 |
| 30 Sep 19 | 169 | 68 | 27 | 81 |
| 30 Jun 19 | 137 | 46 | 25 | 72 |
| 31 Mar 19 | 95 | 10 | 23 | 66 |
| 31 Dec 18 | 47 | -29 | 20 | 58 |
| 30 Sep 18 | 16 | -54 | 19 | 53 |
| 30 Jun 18 | 14 | -54 | 18 | 51 |
| 31 Mar 18 | 22 | -44 | 16 | 51 |
| 31 Dec 17 | 31 | -35 | 13 | 54 |
| 30 Sep 17 | 31 | -34 | 20 | 49 |
| 30 Jun 17 | 23 | -46 | 25 | 49 |
| 31 Mar 17 | 13 | -60 | 32 | 46 |
| 31 Dec 16 | 4 | -75 | 42 | 40 |
| 30 Sep 16 | 0 | -82 | 25 | 61 |
| 30 Jun 16 | 0 | -84 | 41 | 39 |
| 31 Mar 16 | 0 | -81 | 40 | 37 |
| 31 Dec 15 | 0 | -89 | 36 | 39 |
| 30 Sep 15 | 0 | -92 | 35 | 47 |
| 30 Jun 15 | 0 | -90 | 32 | 45 |
| 31 Mar 15 | 0 | -85 | 30 | 44 |
| 31 Dec 14 | 0 | -71 | 28 | 37 |
Quality Earnings: ARWR is currently unprofitable.
Growing Profit Margin: ARWR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARWR is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare ARWR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARWR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (65.2%).
Return on Equity
High ROE: ARWR has a negative Return on Equity (-30.66%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 13:36 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arrowhead Pharmaceuticals, Inc. is covered by 31 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |